News articles about FibroGen (NASDAQ:FGEN) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. FibroGen earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 43.8539046956304 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Several research firms recently weighed in on FGEN. Mizuho began coverage on FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price target on the stock. Stifel Nicolaus reissued a “buy” rating and set a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC reissued a “buy” rating and set a $75.00 price target on shares of FibroGen in a research report on Tuesday, September 12th. William Blair reissued an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Finally, Leerink Swann reissued an “outperform” rating and set a $82.00 price target (up from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $65.67.

FibroGen (NASDAQ:FGEN) opened at 55.15 on Wednesday. The firm’s market capitalization is $3.93 billion. The firm has a 50-day moving average price of $50.58 and a 200 day moving average price of $35.73. FibroGen has a 12 month low of $15.60 and a 12 month high of $60.15.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The firm had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. On average, equities analysts forecast that FibroGen will post ($1.81) EPS for the current year.

In other FibroGen news, Director Jorma Routti sold 12,000 shares of FibroGen stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $47.36, for a total value of $568,320.00. Following the sale, the director now owns 133,840 shares of the company’s stock, valued at approximately $6,338,662.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $35.09, for a total value of $1,355,737.24. Following the completion of the sale, the chief executive officer now directly owns 3,330,780 shares in the company, valued at approximately $116,877,070.20. The disclosure for this sale can be found here. Insiders sold a total of 552,828 shares of company stock worth $26,593,147 in the last three months. Company insiders own 14.90% of the company’s stock.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect FibroGen (FGEN) Stock Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.